Article Text

PDF
▼Quinupristin + dalfopristin for infections

Abstract

&#9660Quinupristin + dalfopristin* (Synercid-Aventis Pharma Ltd) is a new combination antibacterial product licensed for treating patients with a variety of Gram-positive infections. Here we assess its place in clinical practice.

Statistics from Altmetric.com

  • Relevant BNF section: 5.1.7

View Full Text

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.